COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is currently being treated using Remdesivir, a nucleoside analog that inhibits the RNA-dependent-RNA polymerase (RdRp). However, the enzymatic mechanism and efficiency of Remdesivir have not been determined...
Remdesivir was one of the first medications approved for treatment of COVID-19. Clinical studies evaluated its effectiveness, but did not generate conclusive results. A new analysis of the study data shows that a specific group of patients benefits the most from the drug. Since the outbreak of ...
First off, the drug is nota cure for COVID-19. Results of the coronavirus trial — which was sponsored by the National Institute of Allergy and Infectious Diseases — found that recovery time for patients who took remdesivir was 11 days, as compared to 15 days for patients in the control ...
Previously remdesivir was available only via an emergency use authorization (EUA) to treat COVID-19. Veklury is approved for use in patients 12 years of age and older and weighing at least 40 kg (88 lb) for the treatment of COVID-19 who require hospitalization. It is given via ...
According to Gilead:“Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19.” The company clarified that the medication “does not have established safety or effic...
There is no effective cure for SARS-CoV-2 infection and the most common treatment for patients with COVID-19 is supportive care. Although multiple anti-viral drugs, including remdesivir and lopinavir plus ritonavir, have been used in clinical practice,5, 6 the safety and efficacy of these are...
With a primary focus on COVID-19 and its current treatment methods, the present review looks into the potentials of MSCs and MSC-derived exosomes in battling the ongoing pandemic. Finally, the research will draw an analogy between exosomes and their parental cells, when it comes to the ...
B.Doctors had seen noticeable success treating a 35-year-old patient infected with the virus. C.Remdesivir can cure those who are infected with the novel coronavirus. D.Chinese Hospital does The Phase III trials independently. 3. What’s the author's attitude towards the clinical trial of re...
FNC achieved great success in treating patients suffering from COVID-19 during the SAR-CoV-2 outbreak 2020 in China (see results below); the clinical dose of FNC was 5 mg per day in oral administration, much lower than that of remdesivir (100 mg per day, iv) and favipiravir (1000...
globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the ...